🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06501222
Recruiting Not applicable

The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease

NCT06501222 · tracked via the Priya Life Science China tracker
Sponsor
Yuanjun Yang
Phase
Not applicable
Started
2024-03-01
Last updated
2024-08-19

Condition(s) studied

Chronic Kidney Diseases

Investigational drug(s) / intervention(s)

Remote ischemic conditioning

Remote ischemic conditioning: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Study summary

The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote organs via the repeated application of brief ischemic stimuli. the aim of our study is to investigate whether RIC can protect the renal function in patients with CKD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. CKD Patients with eGFR ≥ 15ml/min/1.73m2 2. Age ≥ 18 years old 3. 24-hour urine protein excretion ≤ 3.5g 4. Subjects who have signed the informed consent form Exclusion Criteria: 1. Patients with nephrotic syndrome 2. Patients with acute kidney injury 3. Patients who have undergone renal replacement treatment in the past 4. Patients who may have medication changes during RIC or sham-RIC intervention 5. Patients with a history of diabetes or glycated hemoglobin \> 8% 6. Patients with familial hypercholesterolemia (\>5.5 mmol/L) accompanied by high low-density lipoprotein (\>2.5 mmol/L) 7. Patients with contraindications to RIC, such as vascular injury, soft tissue injury, fracture, infection, or known peripheral vascular disease in both arms 8. Patients with a history of hemostatic disorders, systemic bleeding, or thrombocytopenia 9. Patients with cardiogenic embolism (atrial fibrillation) or other severe arrhythmias (severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia), previous myocardial infarction, or severe heart failure (New York Heart Association Class III and IV) 10. Uncontrolled hypertension (defined as systolic blood pressure ≥ 200 mmHg despite antihypertensive treatment) 11. Patients with respiratory failure, malignant tumors, or other autoimmune diseases 12. Women who are pregnant or breastfeeding at the time of enrollment or any time during the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
chinese PLA general hospital Beijing Beijing Municipality Recruiting

More Yuanjun Yang trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06501222 on ClinicalTrials.gov ↗ ← All trials in China